Lundbeck and Novo-backed nausea and vomiting therapy developer Acacia Pharma raised $49.6m in its initial global offering in Brussels.
Acacia Pharma, a UK-based nausea and vomiting treatment developer backed by pharmaceutical firms Novo and Lundbeck, raised €40m ($49.6m) in an initial global offering on the Euronext Brussels market on Monday.
The company had issued approximately 11.1 million shares priced at €3.60 each to institutional investors in the US, the UK and Europe. The share price briefly rose to €3.80 post-offering and the shares are trading at €3.61 at the time of writing.
Founded in 2007, Acacia is working on…
